Education
About Us
Working with TipRanks
Follow Us
BioInvent International AB (SE:BINV)
:BINV
RESEARCH TOOLSreports
Top Page
BioInvent International AB
(OTC:BINV)
54Neutral
BioInvent International AB (BINV) vs. S&P 500 (SPY)
Market Cap
$2.17B
Dividend YieldN/A
Average Volume (3M)76.73K
Price to Earnings (P/E)―
Beta (1Y)0.43
Revenue Growth-0.57%
EPS Growth-39.92%
CountrySE
Employees118
SectorHealthcare
Sector Strength46
IndustryBiotechnology
Share Statistics
EPS (TTM)-7.11
Shares Outstanding65,804,360
10 Day Avg. Volume64,061
30 Day Avg. Volume76,733
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
BioInvent International AB Business Overview & Revenue Model
Company DescriptionBioInvent International AB (BINV) is a biotechnology company based in Sweden that focuses on the discovery and development of innovative immuno-modulatory antibodies for the treatment of cancer. The company operates primarily in the pharmaceutical and biotechnology sectors, leveraging its proprietary technology platforms to identify and develop drug candidates that target the tumor microenvironment and enhance the body's immune response to cancer.
How the Company Makes MoneyBioInvent International AB generates revenue primarily through partnerships and collaborations with other pharmaceutical and biotechnology companies. These collaborations often involve licensing agreements, where BioInvent provides access to its proprietary technology platforms and expertise in antibody discovery and development in exchange for upfront payments, milestone payments, and royalties on future sales of successfully developed drugs. Additionally, the company may receive funding from research grants and government support, as well as potential earnings from its own clinical-stage drug candidates once they reach the market. Key revenue streams include licensing fees, milestone payments, and royalties from strategic partnerships, which are crucial for financing its research and development activities.
BioInvent International AB Financial Statement Overview
Summary
BioInvent International AB faces significant financial challenges, with declining revenues and persistent losses impacting profitability. The balance sheet remains a relative strength due to solid equity and a low debt burden. However, the company's inability to generate positive cash flow from operations raises concerns about its long-term sustainability. Strategic adjustments may be necessary to improve operational efficiency and financial performance.Income Statement
The company has experienced a severe decline in revenue over the past few years, with TTM (Trailing-Twelve-Months) revenue significantly lower than previous years. Gross profit margins have remained constant at 100%, indicating that all revenue contributes directly to gross profit. However, the net profit margin is deeply negative, reflecting substantial operating losses. The EBIT and EBITDA margins are also negative, highlighting significant operational challenges.30
Negative
Balance Sheet
The company maintains a strong equity position with an equity ratio of approximately 89% in the TTM period. The debt-to-equity ratio is low, suggesting limited reliance on debt financing. However, the substantial negative net income impacts the return on equity, which remains negative. The company's cash position remains strong, providing some stability amidst operational challenges.60
Neutral
Cash Flow
Operating cash flow has been consistently negative, indicating that the company is not generating enough cash from operations to cover its expenses. Free cash flow has also declined, reflecting increased operational and capital expenditure pressures. Despite these challenges, the company has managed to maintain a positive cash position through financing activities.35
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 44.69M | 71.46M | 326.13M | 19.38M | 147.37M | Gross Profit |
| 44.69M | 71.46M | 326.13M | 19.38M | 147.37M | EBIT |
| -471.06M | -369.94M | -50.92M | -278.35M | -75.47M | EBITDA |
| -409.38M | -312.71M | -27.13M | -263.32M | -63.99M | Net Income Common Stockholders |
| -429.38M | -330.30M | -34.09M | -278.96M | -76.67M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 867.16M | 1.07B | 1.02B | 1.08B | 729.27M | Total Assets |
| 989.24M | 1.40B | 1.71B | 1.45B | 802.64M | Total Debt |
| 17.41M | 23.24M | 26.96M | 28.37M | 11.60M | Net Debt |
| -417.41M | -236.30M | -488.08M | -882.39M | -717.67M | Total Liabilities |
| 103.42M | 90.45M | 106.09M | 80.32M | 59.14M | Stockholders Equity |
| 885.82M | 1.31B | 1.61B | 1.37B | 743.50M |
| Cash Flow | Free Cash Flow | |||
| -390.50M | -355.00M | -53.60M | -259.10M | -69.32M | Operating Cash Flow |
| -380.47M | -341.69M | -41.23M | -245.84M | -62.62M | Investing Cash Flow |
| 564.35M | 59.68M | -628.85M | -467.54M | -6.70M | Financing Cash Flow |
| -8.46M | 23.14M | 273.49M | 894.87M | 644.62M |
BioInvent International AB Technical Analysis
Positive
32.60
Price Trends
28.98
Positive
29.92
Positive
36.49
Negative
Market Momentum
1.36
Negative
59.09
Neutral
75.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BINV, the sentiment is Positive. The current price of 32.6 is above the 20-day moving average (MA) of 29.86, above the 50-day MA of 28.98, and below the 200-day MA of 36.49, indicating a neutral trend. The MACD of 1.36 indicates Negative momentum. The RSI at 59.09 is Neutral, neither overbought nor oversold. The STOCH value of 75.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BINV.
BioInvent International AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | kr1.12B | 5.10 | 179.17% | ― | 1887.36% | ― | |
54 Neutral | $2.17B | ― | -45.80% | ― | -0.57% | -39.92% | |
52 Neutral | $5.15B | 3.56 | -42.52% | 2.83% | 14.56% | -0.53% | |
50 Neutral | kr1.78B | ― | ― | 9.53% | 41.19% | ||
48 Neutral | kr944.89M | ― | -43.97% | ― | ― | 67.70% | |
47 Neutral | €1.09B | ― | -42.24% | ― | ― | -19.44% | |
45 Neutral | €1.85B | ― | -40.15% | ― | ― | 63.85% |
* Healthcare Sector Average
Performance Comparison
SE:BINV
BioInvent International AB
32.60
6.55
25.14%
SE:HNSA
Hansa Biopharma AB
25.94
-9.24
-26.26%
SE:SANION
Saniona AB
8.00
6.20
344.44%
SE:VICO
Vicore Pharma Holding AB
7.94
-12.54
-61.23%
SE:XSPRAY
Xspray Pharma AB
32.10
-13.35
-29.38%
SE:SYNACT
SynAct Pharma AB
18.82
11.78
167.33%
BioInvent International AB Earnings Call Summary
Earnings Call Date:Apr 29, 2025
(Q3-2024)
| % Change Since: 11.26%|
Next Earnings Date:Aug 26, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in clinical trials and strategic collaborations, with promising data in lead compounds and strong financial reserves. However, these positives are counterbalanced by decreased net sales, increased operating costs, and significant financial losses.Q3-2024 Updates
Positive Updates
Positive Data for Lead Compound BI-1206
The company reported additional positive data for their lead compound BI-1206, targeting FcgammaRIIB, especially for the subcutaneous formulation, with 2 complete responses, 3 partial responses, and 3 stable diseases out of 9 evaluable patients.
Progress in BI-1808 and BI-1910 Programs
BI-1808 showed 3 partial responses and 1 stable disease out of 4 evaluable patients in the CTCL cohort. BI-1910 received a Notice of Allowance and showed robust target occupancy in trials.
Successful Subcutaneous Formulation
The subcutaneous (subcu) formulation of BI-1206 showed improved activity and safety profile compared to the intravenous version, eliminating infusion-related reactions.
Strategic Collaborations
New clinical trial collaboration and supply agreements were established with Merck for BI-1607, and with AstraZeneca for BI-1206 in a triplet combination with rituximab and acalabrutinib.
Promising Anti-CTLA-4 Antibody Data
The anti-CTLA-4 antibody in combination with pembrolizumab showed tumor regression in patients who failed previous anti-PD-L1 treatment.
Strong Financial Position
The company has liquid funds of SEK 979 million, providing a financial runway until the end of Q1 2026.
Negative Updates
Decrease in Net Sales
Net sales decreased by SEK 14 million in Q3 2024 compared to Q3 2023, and by SEK 33 million for the January to September period in 2024 compared to the same period in 2023.
Increased Operating Costs
Operating costs increased by SEK 12 million in Q3 2024 compared to Q3 2023, and by SEK 53 million for the January to September period in 2024 compared to the same period in 2023.
Significant Losses
The company reported a loss of SEK 97.2 million for Q3 2024 and a loss of SEK 312.5 million for the January to September period in 2024.
Company Guidance
During the BioInvent Q3 2024 earnings call, CEO Martin Welschof and CFO Stefan Ericsson provided extensive guidance on the company's development programs, highlighting several key metrics. The company reported net sales of SEK 12.8 million for Q3 2024, a decrease from SEK 26.8 million in Q3 2023, primarily due to the absence of a $1 million milestone achieved in the previous year. Operating costs increased to SEK 120 million compared to SEK 108 million in Q3 2023, partly due to higher costs associated with their BI-1607 and BI-1808 programs. The loss for Q3 2024 was reported as SEK 97.2 million. The company emphasized the promising progress of its lead compounds, including BI-1206, BI-1808, and BI-1910, with significant developments in both subcutaneous and intravenous formulations, notably in achieving complete and partial responses in clinical trials. They anticipate further data releases by the end of the year and into 2025, which could drive substantial value and strategic opportunities, including potential partnerships. BioInvent's liquid funds at the end of September amounted to SEK 979 million, providing a runway until Q1 2026, and the management expressed optimism about securing collaborations to bolster their financial position.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.